Meglumine antimoniate
From Wikipedia, the free encyclopedia
 | |
|---|---|
| Systematic (IUPAC) name | |
| Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol | |
| Clinical data | |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Legal status | ? |
| Identifiers | |
| CAS number | 133-51-7  |
| ATC code | P01CB01 QP51AB01 |
| PubChem | CID 64953 |
| ChemSpider | 58479  |
| ChEMBL | CHEMBL239129 |
| NIAID ChemDB | 008733 |
| Chemical data | |
| Formula | Variable |
| Mol. mass | Variable |
| SMILES
| |
| |
| (what is this?) (verify) | |
Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis.[1] It is manufactured by Aventis[2] and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.
See also
References
- ↑ Soto, J.; Fuya, P.; Herrera, R.; Berman, J. (1998). "Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: Controlled study". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 26 (1): 56–58. PMID 9455509.
- ↑ Aventis press release, 15 April 2005. (German)
| |||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.